Aurobindo Pharma acquires domestic formulations business of Veritaz Healthcare for Rs 171 crore

Aurobindo Pharma Ltd has announced the acquisition of the domestic formulation business of Veritaz Healthcare for a consideration of Rs. 171 crore on debt-free cash-free basis. With this acquisition, Aurobindo marked its first step to set its footprint in the Indian domestic market as announced earlier. The transaction comes into effect from April 1, 2022 and is expected to close by May 2022. This acquisition vehicle will greatly help Aurobindo as a launch pad for marketing biosimilar and other products in India. Veritaz is a 10+ years old company with an audited turnover of Rs. 133 crore for the period of 9 months ended December 2021 and it had a turnover of Rs. 127 crore for the full year FY 2021. Its current product portfolio operates in an addressable market of Rs. 26,775 crore which is an exciting space to gain market share and grow our business. The company has around 40 brands across the acute and critical care segments. The total number of trademarks registered in its name is around 180. Its largest brands are Fepanil and Merogram group which clock a revenue of around Rs. 31 crore and Rs. 20 crore up to December 2021 respectively. Currently, the company caters to anti-infective and pain-management therapeutic areas and has a pipeline of products to enter into the cardio/diabetic and ortho/gynaecology segments. The company has an existing sales and distribution network with 900 field force, covering more 50,000 retailers with nearly 1,700 stockiest, presence in 23 cities, reaching out to more than 70,000 doctors and empanelled with major hospitals. Commenting on the development, K Nithyananda Reddy, managing director, said,

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!